Biotechnology Methods

Biotechnology for the MCAT

Part 1 of 4 — Cutting, Pasting & Copying: Restriction Enzymes, Cloning & PCR

Restriction Enzymes — Molecular Scissors with Addresses

• Bacterial defense enzymes (paired with methylases that protect the host's own sites) that cut DNA at specific palindromic recognition sequences — read the same 5' to 3' on both strands (EcoRI: GAATTC).
• Sticky ends: staggered cuts leave complementary single-stranded overhangs — any two fragments cut by the SAME enzyme can anneal, regardless of source ("recombinant"). Blunt ends: straight cuts, ligatable but inefficient and unselective.
• DNA ligase seals the annealed fragments with real phosphodiester bonds — the paste to the scissors.
• Fragment counting: a LINEAR molecule with n cut sites yields n+1 fragments; a CIRCULAR molecule (plasmid) with n sites yields n fragments. Expect arithmetic.

Cloning a Gene — The Assembly Line

1. Cut vector (usually a plasmid: circular, autonomously replicating, with an origin of replication so it is copied and passed to daughter cells, a selectable marker like an antibiotic-resistance gene, and a multiple cloning site) and insert with the same enzyme(s).
2. Ligate; transform into bacteria (the cells take up the plasmid).
3. Select: plate on the antibiotic — only plasmid-bearing cells grow.
4. Screen for insert-containing plasmids: classic blue-white screening — the cloning site interrupts lacZ, so insert-bearing colonies stay WHITE on X-gal (functional lacZ = blue = empty vector).

• Bacteria are made "competent" to take up DNA by heat shock (with calcium chloride) or by electroporation.

Expressing human protein in bacteria has a catch: bacteria cannot splice. Clone the cDNA (reverse-transcribed from mature mRNA — intron-free), not genomic DNA, and put it behind a bacterial promoter. Insulin is the classic product. Proteins needing glycosylation or complex folding move to yeast/mammalian cells — no ER, no N-glycans in E. coli.

• DNA libraries: a genomic library holds all of an organism's DNA, including introns and noncoding regions; a cDNA library is made from mRNA, so it holds only the genes expressed in that tissue, with no introns — the right source for expressing eukaryotic genes in bacteria.

PCR — Copying Without Cells

Each cycle, three temperature steps:

• Amplification is exponential: ~$2^n$ copies after n cycles (30 cycles = ~$10^9$).
• Primers define the product: they bind the 3' ends of the target region ON THE TEMPLATE strands so synthesis runs INTO the target. Primer design questions = reverse-complement bookkeeping.
• Everything the reaction needs is in the tube: template, primers, dNTPs, Taq, Mg$^{2+}$ — no helicase (heat unwinds), no primase (primers supplied), no ligase (products are continuous).
• Variants to recognize: RT-PCR (reverse transcriptase first — amplify from mRNA), qPCR (fluorescence each cycle quantifies starting material: earlier threshold = more template).

Worked Example — A Cloning Experiment That Fails Informatively

Passage-style problem. A student clones a human liver enzyme's coding sequence into a plasmid carrying ampicillin resistance and lacZ-based blue-white screening, transforms E. coli, and plates on ampicillin + X-gal.

• Observation 1: 200 colonies grow; 150 blue, 50 white.
• Observation 2: white colonies contain plasmid with insert (confirmed by restriction digest), but the enzyme is inactive, and western blot shows a protein LARGER than the mature human enzyme.
• Observation 3: repeating the project with a construct made from liver mRNA yields active enzyme of correct size — but only when expressed in yeast, not in E. coli, where the protein is correct in backbone size yet still inactive.

Question 1 — Interpret the blue vs white colonies. All 200 took up SOME plasmid (ampicillin selection). Blue = lacZ intact = vector re-ligated on itself without insert (the dominant product when ligation conditions favor self-closure); white = lacZ interrupted = insert present. Selection eliminates non-transformants; screening distinguishes insert from empty vector — two different steps answering two different questions.

Question 2 — Why is the first insert's protein too large and dead? (It was amplified from GENOMIC DNA.) Genomic DNA contains introns. E. coli has no spliceosome, so introns are transcribed AND translated (until a frameshift or premature stop intervenes) — an oversized, garbled protein. The fix in Observation 3: start from mRNA, reverse-transcribe to cDNA (splicing already done by the human cell), then clone.

Question 3 — Why does the cDNA product work in yeast but not E. coli? Correct backbone size in E. coli means the coding is fine — the missing ingredient is post-translational: the liver enzyme evidently needs eukaryotic machinery (N-glycosylation in the ER, disulfide formation, chaperone-assisted folding). Yeast, a eukaryote, supplies it. Host choice is a real experimental variable: bacteria for cheap simple proteins, eukaryotic systems for modified ones.

Question 4 — The student's primers amplified the coding sequence but the yeast strain secretes none of the enzyme into the medium. What sequence must be added to the construct? A signal peptide coding sequence at the 5' end of the ORF — without an ER-targeting signal, the protein stays cytosolic (Organelles Part 2 crossover). Constructs are modular: promoter, signal, ORF, tag — each function needs its module.

Cloning & PCR 🎯

Key Takeaways — Part 1

• Restriction enzymes cut palindromes; sticky ends anneal any same-enzyme fragments; ligase seals; count fragments as n (circular) vs n+1 (linear)
• Cloning pipeline: cut vector + insert with the same enzyme, ligate, transform, SELECT with antibiotic (who has plasmid), SCREEN blue-white (who has insert — white = interrupted lacZ = success)
• Vector anatomy: origin of replication, selectable marker, multiple cloning site; constructs are modular (promoter, signal peptide, ORF, tag)
• Express human proteins from cDNA (reverse-transcribed mRNA, intron-free) because bacteria cannot splice; move to yeast/mammalian hosts when glycosylation or complex folding is required
• PCR: denature ~95 C, anneal primers ~55 C, extend ~72 C with thermostable Taq; heat replaces helicase, supplied primers replace primase; no proofreading in Taq
• Amplification = initial times 2 to the n; 2^10 is about 10^3 — estimate, do not compute
• qPCR quantifies (earlier threshold = more starting template); RT-PCR reaches back to mRNA via reverse transcriptase

• Low-yield extras: bacteria are made competent for transformation by heat shock or electroporation

Biotechnology for the MCAT

Part 2 of 4 — Reading DNA: Gels, Blots & Sequencing

Gel Electrophoresis — The Universal Readout

• DNA's phosphate backbone gives uniform negative charge, so an electric field pulls all fragments toward the positive electrode (anode); the agarose mesh sieves them so small fragments run FAR, large fragments stay near the wells.
• Migration distance falls roughly linearly as log(size) rises — a ladder of standards calibrates the gel.
• Proteins need a trick first: SDS coats them with uniform negative charge and unfolds them, so SDS-PAGE separates by size alone. (Native gels and isoelectric focusing separate by shape/charge — know which gel answers which question.)

The Blot Family — Specificity via Probes

Mnemonic: SNoW DRoP (Southern-DNA, Northern-RNA, Western-Protein). A blot = electrophoresis + transfer to membrane + probe; the probe's specificity is what turns a smear of molecules into one interpretable band.

• RFLP analysis (Southern application): a mutation that creates/destroys a restriction site changes fragment sizes — sickle cell's mutation famously destroys a restriction site in the beta-globin gene, so the mutant allele shows one LARGER band. Genotyping by band pattern: homozygotes show one pattern, heterozygotes show BOTH.

• The enzyme whose site the sickle mutation destroys is MstII.

Sanger Sequencing — Chain Termination as Information

• The reaction: template, ONE primer, polymerase, all four dNTPs, PLUS a small fraction of dideoxynucleotides (ddNTPs) — no 3'-OH, so incorporation TERMINATES the chain.
• Nucleoside-analog drugs (e.g., AZT, acyclovir) use the same missing-3'-OH logic: once incorporated, the chain cannot be extended.
• Each termination event marks the position of that base; run the nested fragment family on a high-resolution gel and read bands from the bottom (shortest) up — that is the new strand 5' to 3'.
• The read is the COMPLEMENT of the template: to report the template, reverse-complement your read. Modern automation = four fluorescent ddNTP colors, one capillary lane.
• Next-generation sequencing (conceptual level): massively parallel short reads, assembled by overlap — cheaper per base, used for whole genomes/exomes and RNA-seq (sequence cDNA to census the whole transcriptome, replacing microarrays).

Reading Band Patterns Like the Exam Wants

• MORE bands than expected in a digest: extra restriction site (polymorphism) or partial digestion.
• Band SHIFT on a northern: alternative splicing or different transcript; on a western: PTM (phosphorylation slows migration slightly), cleavage (smaller), or glycosylation (larger, fuzzy).
• Signal in DNA (Southern) but absent in RNA (northern): gene present but not transcribed in this tissue — a regulation story, not a deletion.

Worked Example — One Family, Three Blots

Passage-style problem. A recessive disease gene is studied in a family. The normal allele cut with enzyme X yields fragments of 3 kb + 2 kb on a Southern blot probed within the region; the disease allele has lost the internal X site, yielding a single 5 kb band. Both parents are unaffected; they have one affected child and one unaffected child.

Question 1 — Predict each family member's Southern pattern. The affected child (two disease alleles): 5 kb only. Both parents must be carriers: 5 kb AND 3 kb AND 2 kb — all three bands (each parent has one normal allele contributing 3+2 and one mutant contributing 5). The unaffected sibling: either three bands (carrier, probability 2/3 among unaffected offspring) or two bands (3+2 only; homozygous normal, probability 1/3). Genotype-to-band-pattern translation plus Mendelian probability in one question — a classic MCAT fusion.

Question 2 — A northern blot of the affected child's tissue shows normal-size, normal-abundance mRNA. What does this add? The mutation does not prevent transcription or grossly alter the transcript — consistent with the lost restriction site being a point mutation (missense) rather than a large deletion. The lesion's effect must appear at the protein level or beyond.

Question 3 — A western blot shows the affected child's protein at normal size but reduced 10-fold in amount. Propose a mechanism. Normal size argues against truncation; reduced quantity with normal mRNA points to post-translational loss — a missense change that destabilizes folding, with quality-control degradation removing most molecules (the deltaF508 logic from the translation lesson). A pulse-chase (normal pulse labeling, fast chase decay) would confirm accelerated turnover over reduced synthesis.

Question 4 — Sanger sequencing of the affected child's allele uses a primer just upstream of the suspected codon. The lane read (new strand, bottom to top) begins 5'-CACGTG...-3' where the normal read begins 5'-CACGAG...-3'. Name the DNA change. Align the reads: position 5 shows A-to-T... careful — the read is the NEW strand; the template base changed from T (pairs A) to A (pairs T). Report it on the coding convention the passage uses, and only then translate to an amino acid change. The orientation discipline — read strand vs template vs coding — is where sequencing questions are won or lost.

Gels, Blots & Sequencing 🎯

Key Takeaways — Part 2

• Electrophoresis: uniform negative DNA pulled to the anode; the GEL separates by size (small runs far; migration distance falls roughly linearly as log(size) rises); SDS gives proteins the same uniform charge for SDS-PAGE
• Chain terminators: ddNTPs, and nucleoside-analog drugs (AZT, acyclovir), lack a usable 3'-OH
• SNoW DRoP: Southern = DNA (gene present, copy number, RFLP), northern = RNA (transcribed? transcript size/splicing), western = protein (made? size? amount?) — probes are DNA/RNA for the first two, antibodies for the third
• RFLP: site destroyed = fewer, larger fragments; heterozygotes show BOTH allele patterns — genotyping from band patterns plus Mendelian probability
• Sanger: ddNTPs lack the 3'-OH, terminating chains at random positions of one base; read the gel bottom-up = new strand 5' to 3'; the read is the template's complement — reverse-complement before reporting
• NGS/RNA-seq: probe-free, massively parallel, finds novel transcripts and splice variants; microarrays are hybridization to known probes
• Interpretation habits: extra bands = extra site or partial digest; DNA present but no RNA = regulation, not deletion; western shifts = PTM, cleavage, or glycosylation

• Low-yield extras: the sickle mutation destroys an MstII site

Biotechnology for the MCAT

Part 3 of 4 — Manipulating Genes in Cells & Organisms

Turning Genes Off (and Down)

• CRISPR interference (CRISPRi): a catalytically dead Cas9, guided to the promoter, blocks transcription without altering the sequence — reversible, at the transcription level.

Interpretation rules: knockouts reveal what a gene is REQUIRED for (but beware developmental compensation and lethality); knockdown's residual expression can mask phenotypes; a knockout phenotype rescued by re-introducing the gene proves causality (the rescue is the control that eliminates off-target explanations).

CRISPR-Cas9 — Programmable Cutting

• A guide RNA base-pairs with a chosen ~20 bp genomic sequence; Cas9 makes a double-strand break there. Targeting is by RNA-DNA base pairing — reprogramming means changing a 20-nt RNA, not engineering a new protein.

• The target must sit next to a short PAM motif that Cas9 itself recognizes. Earlier editors (zinc-finger nucleases, TALENs) needed a newly engineered protein for every site, which is why CRISPR displaced them.

• The CELL's repair choice determines the outcome (DNA replication lesson crossover): NHEJ = error-prone indels → frameshift knockout; HDR with a supplied template = precise edits/insertions (efficient mainly in dividing cells).
• Origin: a bacterial adaptive immune system that stores snippets of past phage DNA as "mug shots" to recognize and cut repeat invaders — a natural defense repurposed as a lab tool, just like restriction enzymes.

Transgenics, Knock-ins & Conditional Control

• Transgenic organism: foreign/extra DNA added (often random insertion; expression depends on the promoter you attach — a tissue-specific promoter confines expression to that tissue).
• Knock-in: precise replacement at the endogenous locus (keeps native regulation).
• Cre-lox conditional knockout: the target gene is flanked by loxP sites ("floxed"); Cre recombinase excises it — but ONLY in cells where Cre is expressed. Cre under a liver-specific promoter = gene deleted in liver alone. Solves embryonic lethality and isolates tissue-specific function; the exam loves asking WHY conditional systems are needed.
• Reporter fusions: GFP fused to a protein reports localization; a promoter driving GFP alone reports WHERE/WHEN the promoter is active — different constructs, different questions.

Gene Therapy — Delivery Is the Hard Part

• Add a working gene copy (viral vectors: AAV — small capacity, low immunogenicity, largely non-integrating; retro/lentivirus — integrates into the genome = durable but insertional mutagenesis risk: a vector landing beside a proto-oncogene can switch it on).

• Historical anchor: early retroviral SCID gene-therapy trials caused leukemias when the vector integrated beside the proto-oncogene LMO2.

• Ex vivo strategy: remove patient cells (e.g., hematopoietic stem cells), correct them in culture, verify, reinfuse — sickle cell and SCID successes; safer because correction is checked before return.
• Somatic editing affects the patient only; germline changes are heritable — the ethical bright line passages probe.

Worked Example — Designing the Right Perturbation

Passage-style problem. Gene Q is hypothesized to drive pathological cardiac hypertrophy in adult mice. Complication: Q-null embryos die at day 10 from failed heart tube formation.

Question 1 — Why is a conventional knockout the wrong tool, and what replaces it? The gene has an EARLIER essential function: constitutive deletion kills the embryo before adult hypertrophy can be studied — the lethality masks the phenotype of interest. Solution: conditional knockout — flox Q, and supply Cre under a cardiomyocyte-specific promoter in a drug-inducible form (Cre stays inactive until the drug is given), so deletion happens only in heart muscle AND only when the adult mouse is dosed. Space and time are separate switches; the design needs both — a heart-specific promoter alone would still delete Q in the embryonic heart tube.

The standard inducible version is CreER: Cre fused to a modified estrogen-receptor domain, held outside the nucleus until tamoxifen frees it.

Question 2 — The team also tries siRNA against Q in cultured cardiomyocytes and sees only a 60% mRNA reduction with no phenotype. A colleague concludes Q is not involved. Critique. Knockdown is not knockout: 40% residual protein may exceed the functional threshold, especially for catalytic proteins where a little enzyme suffices. Absence of phenotype under PARTIAL loss cannot exclude the hypothesis — only complete (conditional) deletion, or a dominant-negative, tests requirement cleanly.

Question 3 — Conditional deletion in adult hearts prevents hypertrophy after pressure overload. What single further experiment most strengthens causality? Rescue: re-express Q (knock-in or viral delivery) in the deleted hearts and show hypertrophy returns. Rescue excludes off-target Cre effects, floxing artifacts, and strain background — the perturbation-rescue pair is the causal gold standard, exactly parallel to reintroducing a cloned gene into a knockout line.

Question 4 — To ask whether Q acts in cardiomyocytes themselves versus cardiac fibroblasts, what feature of the Cre system is decisive? Promoter choice: Cre driven by a cardiomyocyte promoter deletes Q only there; a fibroblast-promoter Cre line deletes it only in fibroblasts. If hypertrophy persists in the first and disappears in the second, Q acts in fibroblasts (cell-non-autonomous). Tissue-specific promoters convert a molecular tool into a cell-biology scalpel — and this promoter-defines-place logic is identical for GFP reporters and transgenes.

Gene Manipulation 🎯

Key Takeaways — Part 3

• Perturbation hierarchy: knockout = permanent DNA-level absence (requirement); knockdown (RNAi) = partial, reversible RNA-level reduction — residual protein can hide phenotypes; dominant negative poisons at the protein level
• CRISPR: guide RNA base-pairing (not protein engineering) targets Cas9's cut; the cell's repair choice sets the outcome — NHEJ indels = knockout, HDR + template (S/G2, dividing cells) = precise knock-in
• Conditional (Cre-lox) systems separate deletion in space (tissue-specific promoter) and time (drug-inducible Cre) — the answer whenever early lethality masks a later function
• Promoter-GFP reports where a promoter fires; GFP-protein fusions report where the protein goes — match construct to claim
• Rescue experiments (re-express the gene, phenotype reverts) are the causality gold standard against off-target effects
• Gene therapy: integrating vectors (retro/lenti) = durable + insertional mutagenesis risk (proto-oncogene activation); AAV = safer, non-integrating, small capacity; ex vivo correction allows verification before reinfusion
• Somatic editing stays with the patient; germline edits are heritable — the ethical boundary passages test

• Low-yield extras: CRISPR interference (dead Cas9 blocks transcription); the PAM motif beside every Cas9 target; zinc-finger nucleases and TALENs as the protein-engineered predecessors; tamoxifen-activated CreER; the LMO2 leukemias of the early retroviral SCID trials

Biotechnology for the MCAT

Part 4 of 4 — Choosing the Right Tool: Protein Methods & MCAT Integration

The Protein-Side Toolkit

• Yeast two-hybrid asks whether X and Y interact, at screening scale: X and Y are fused to the two halves of a split transcription factor, and their binding reconstitutes it, switching on a reporter gene.

Antibody logic underlies half the table: specificity comes from the antibody; the assay format determines WHAT question (amount, size, place, partner) that specificity answers.

The Master Decision Tree

Ask, in order:

1. What molecule? DNA (Southern, PCR, sequencing) / RNA (northern, RT-qPCR, RNA-seq) / protein (western, ELISA, IF, flow).
2. What property? Amount (qPCR, ELISA) / size or form (blots, gels) / location (IF, GFP fusion, fractionation) / interaction (co-IP, yeast two-hybrid, EMSA for protein-DNA) / function (activity assay, knockout + rescue).
3. In vitro binding, in-cell occupancy, or organismal requirement? — the EMSA vs ChIP vs knockout ladder from the transcription lesson generalizes to every claim.

Stem Cells & Cloning Vocabulary (Light but Tested)

• Potency ladder: totipotent (zygote — any cell INCLUDING placenta) > pluripotent (embryonic stem cells, any embryonic lineage) > multipotent (adult stem cells — hematopoietic SCs make all blood, nothing else).
• iPSCs: adult somatic cells reprogrammed to pluripotency by defined transcription factors — patient-matched, no embryo; the reprogramming itself is evidence that differentiation is epigenetic, not genetic (the genome never changed).
• Reproductive cloning (SCNT): somatic nucleus into an enucleated egg — the clone's NUCLEAR genome matches the donor, but its mitochondrial DNA comes from the egg (a beloved detail).

Passage-Day Integration Checklist

• Name each figure's technique and the ONE claim it can support before reading the answer choices.
• Trust the controls: a result without its control (no-template PCR, isotype antibody, empty vector, scrambled siRNA) supports nothing.
• Quantitative instincts: PCR doubles per cycle; ELISA color scales with analyte; qPCR thresholds run backwards (fewer cycles = more template).
• When two techniques disagree (mRNA up, protein flat), the interesting biology lives between them — regulation at translation or protein stability, not an "error."

Worked Example — Building a Diagnostic and Testing a Mechanism

Passage-style problem. A biotech team studies a suspected autoimmune disease in which patients may make antibodies against their own insulin receptor, blocking insulin binding and causing severe insulin-resistant hyperglycemia.

Question 1 — Design the screening assay for anti-receptor antibodies in patient serum. ELISA: coat plates with purified insulin receptor (the antigen), add patient serum (any anti-receptor antibodies bind), wash, detect with an enzyme-linked anti-HUMAN-IgG secondary antibody, add substrate, read color. Note the inversion of the usual format — here the ANTIBODY is the analyte, so the plate presents antigen. Controls: healthy sera (background), plates coated with an irrelevant protein (specificity).

Question 2 — ELISA-positive patients could carry antibodies that merely bind the receptor without blocking insulin. What experiment distinguishes binding from blocking? A competition/function assay: incubate cultured cells bearing insulin receptors with labeled insulin plus or minus patient antibodies — blocking antibodies reduce insulin binding (or downstream: reduce insulin-stimulated receptor phosphorylation on a western). Binding is not function — the EMSA-vs-reporter lesson in immunological clothing.

Question 3 — One patient is hypoglycemic instead. Propose the mechanism and the confirming result. An antibody can be an AGONIST: by crosslinking receptors it may mimic insulin and activate signaling. Prediction: patient antibody alone (no insulin) triggers receptor autophosphorylation and glucose uptake in cultured cells. Same target, opposite functional sign — receptor antibodies split into blockers (this passage's disease) and activators (the Graves disease TSH-receptor precedent the MCAT expects you to recall).

The blocking anti-insulin-receptor disease is a real, rare syndrome: type B insulin resistance.

Question 4 — The team suspects the pathogenic antibodies arose against a viral protein resembling the receptor (molecular mimicry). What sequence-level evidence would support this, and what technique gathers it? Sequence the viral proteome (or search databases) for a peptide with high identity to the receptor's extracellular epitope; then show patient antibodies bind BOTH peptides (ELISA against each) and that pre-absorbing serum with viral peptide removes anti-receptor reactivity. Cross-reactivity plus absorption is the standard two-step mimicry argument — technique choice, controls, and immunology reasoning in one arc, which is precisely what an MCAT discrete-passage hybrid looks like.

Technique Selection & Integration 🎯

Key Takeaways — Part 4

• Antibody assay formats map to questions: ELISA = how much (fluids; screen), western = present + size (confirm), immunofluorescence = where, flow/FACS = per-cell counting AND live sorting, co-IP = physical association, two-hybrid = interaction screening
• Screen sensitive, confirm specific (HIV ELISA then western) — the universal diagnostic architecture
• Decision tree: molecule (DNA/RNA/protein), then property (amount/size/location/interaction/function), then claim level (in vitro binding, in-cell occupancy, organismal requirement)
• Co-IP shows association, never catalysis or directness; function needs activity assays; requirement needs knockout + rescue
• Stem cell ladder: totipotent > pluripotent (ESC, iPSC) > multipotent; iPSC reprogramming and SCNT prove differentiation is epigenetic over an intact genome; SCNT clones carry the EGG's mitochondrial DNA
• Discordant data are mechanisms in disguise: mRNA up + protein flat = translational control or turnover — chase it with polysome profiles and pulse-chase
• Before answering any figure question: name the technique, its one supportable claim, and the control that legitimizes it

• Low-yield extras: the blocking anti-insulin-receptor syndrome is type B insulin resistance